Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Johnson and Johnson
McKesson
Colorcon
Baxter

Last Updated: September 26, 2022

Details for Patent: 8,999,313


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,999,313 protect, and when does it expire?

Patent 8,999,313 protects PLENVU and is included in one NDA.

This patent has seventy-seven patent family members in thirty-two countries.

Summary for Patent: 8,999,313
Title:Compositions
Abstract: The invention provides a colon cleansing solution comprising: a) 300 to 800 mmol per liter ascorbate anion provided by a mixture of: (i) ascorbic acid and (ii) one or more salts of ascorbic acid the components (i) and (ii) being present in a molar ratio of from 1:4.5 to 1:7.0; and b) 10 to 200 g per liter polyethylene glycol. The invention also provides methods an kits associated with, or making use of the solutions, and compositions for the preparation of the solutions.
Inventor(s): Clayton; Lucy (Uxbridge, GB), Cockett; Alasdair (Uxbridge, GB), Christodoulou; Mark (Uxbridge, GB), Davidson; Ian (Uxbridge, GB), Farrag; Lynn (Uxbridge, GB), Halphen; Marc (London, GB), Jones; Leighton (Uxbridge, GB), Petrossian; Vanik (Woburn, MA), Stein; Peter (Amsterdam Zuid-Oost, NL), Tisi; David (Woburn, MA), Ungar; Alex (Wigton, GB), Worthington; Jeffrey (Woburn, MA)
Assignee: Norgine BV (Amsterdam Zuid-Oost, NL)
Application Number:14/223,127
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,999,313
Patent Claim Types:
see list of patent claims
Composition; Formulation; Device;

Drugs Protected by US Patent 8,999,313

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Salix PLENVU ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate FOR SOLUTION;ORAL 209381-001 May 4, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Moodys
Harvard Business School
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.